Population pharmacokinetics of oseltamivir when coadministered with probenecid.
about
Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populationsCombination of probenecid-sulphadoxine-pyrimethamine for intermittent preventive treatment in pregnancyOseltamivir Population Pharmacokinetics in the Ferret: Model Application for Pharmacokinetic/Pharmacodynamic Study DesignImpact of different oseltamivir regimens on treating influenza A virus infection and resistance emergence: insights from a modelling studyOseltamivir PK/PD Modeling and Simulation to Evaluate Treatment Strategies against Influenza-Pneumococcus Coinfection.The in vivo efficacy of neuraminidase inhibitors cannot be determined from the decay rates of influenza viral titers observed in treated patientsInterdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics.Oseltamivir and oseltamivir carboxylate pharmacokinetics in obese adults: dose modification for weight is not necessary.Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience.Pharmacokinetics and safety of oseltamivir in patients with end-stage renal disease treated with automated peritoneal dialysisOseltamivir pharmacokinetics and clinical experience in neonates and infants during an outbreak of H1N1 influenza A virus infection in a neonatal intensive care unitInvestigating clinically adequate concentrations of oseltamivir carboxylate in end-stage renal disease patients undergoing hemodialysis using a population pharmacokinetic approach.Safety, tolerability, and pharmacokinetics of intravenous oseltamivir: single- and multiple-dose phase I studies with healthy volunteersPopulation pharmacokinetics of oseltamivir in non-pregnant and pregnant women.The status of pharmacometrics in pregnancy: highlights from the 3(rd) American conference on pharmacometricsTargeting organic anion transporter 3 with probenecid as a novel anti-influenza a virus strategy.Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and non-obese volunteers.Population pharmacokinetics of oseltamivir: pediatrics through geriatrics.Pharmacokinetics of high-dose oseltamivir in healthy volunteers.siRNA Genome Screening Approaches to Therapeutic Drug Repositioning.Pharmacokinetic properties of anti-influenza neuraminidase inhibitors.Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial.Identification of new oral dosing regimens for the neuraminidase inhibitor oseltamivir in patients with moderate and severe renal impairment.Population pharmacokinetic analysis of oseltamivir and oseltamivir carboxylate following intravenous and oral administration to patients with and without renal impairment.The Mechanisms for Within-Host Influenza Virus Control Affect Model-Based Assessment and Prediction of Antiviral TreatmentThe posology of oseltamivir in infants with influenza infection using a population pharmacokinetic approach.Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants.Oseltamivir for treatment and prophylaxis of influenza infectionNeuraminidase Inhibitors in Influenza Treatment and Prevention⁻Is It Time to Call It a Day?
P2860
Q24630906-AFCA76CE-8D4E-47AA-B333-09B4A8FA4EECQ27005614-73C20D09-5A24-4833-BF52-2D9DD1807EC7Q27317735-184CAF45-E264-406A-8E6A-7076D19F313EQ28537982-C02BB32D-AF2E-4B13-8909-485D66C2D5C9Q30390145-013B10A6-B0D6-4D9F-8AFA-0377DEE3DA28Q30397216-A5CEB341-B64C-4482-97AE-EE6763F54719Q30398368-68C5A50A-B28C-4EEA-AB5C-3A477D4D980CQ30407250-85A94BA1-29C9-49AC-A346-0FF249FFB9C6Q30409023-FEB21621-040C-42CB-8A58-90828BBE2ACDQ35286102-B2833EB3-484D-4EFF-B468-966B03E212A6Q36086446-07D6942E-3076-4BE5-B737-3C4899A6CF03Q36158241-4DD22B51-39FF-4E75-8B45-879279DB1353Q36172477-2775CD5C-042D-4146-9D11-E288A58FB79AQ36243630-62016EF0-B848-4E00-A8A8-6D15B1F9B0E8Q36468109-042039F6-48E2-49EE-8396-BD123270EAE2Q36505517-BF36D599-42AF-4DBD-934A-524B27B30A0DQ36924693-5F3C38C9-EEF8-4247-BFC3-46BF854FF696Q37036527-1553E154-EA5D-4DCB-8A1C-5AE018DE0B45Q37115683-EB1AEFF2-7F5C-477A-BC6B-1D200A6020EBQ37277365-3E997971-9921-4153-9E77-2D36994D53F9Q38084212-517C2734-0C21-435B-8633-C04075CB4D97Q38375170-2BDCB5F8-DD5F-418E-AD23-E4682C9103DCQ39802403-0569EBAB-A2CA-4F20-9C9A-993B08FD36EAQ41143036-37EAEC7C-955F-423C-82A4-B4D8AC43444DQ41589233-60EC082F-4E42-4CA2-84C9-5DFE9E32CF9DQ42216493-970F638F-AEAA-4B70-98B8-536049E208EDQ43663687-608DD968-63F8-445B-86BF-9C444D0EF68BQ56785849-7B948325-00B4-433E-93D0-BA47810E5F0DQ57093850-AD100451-3889-4CE8-8293-8F7E852AE70C
P2860
Population pharmacokinetics of oseltamivir when coadministered with probenecid.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Population pharmacokinetics of oseltamivir when coadministered with probenecid.
@en
Population pharmacokinetics of oseltamivir when coadministered with probenecid.
@nl
type
label
Population pharmacokinetics of oseltamivir when coadministered with probenecid.
@en
Population pharmacokinetics of oseltamivir when coadministered with probenecid.
@nl
prefLabel
Population pharmacokinetics of oseltamivir when coadministered with probenecid.
@en
Population pharmacokinetics of oseltamivir when coadministered with probenecid.
@nl
P2093
P2860
P356
P1476
Population pharmacokinetics of oseltamivir when coadministered with probenecid.
@en
P2093
Craig R Rayner
E Niclas Jonsson
Lauren M Boak
Pascal Chanu
Ronald Gieschke
P2860
P304
P356
10.1177/0091270008320317
P577
2008-06-04T00:00:00Z